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Dystonia is a painful, disabling disease whose cause in many cases remains unknown. It has historically been treated with a
variety methodologies including baclofen pumps, Botox injection, peripheral denervation, and stereotactic surgery. Deep brain
stimulation(DBS) is emerging as a viable treatment option for selected patients with dystonia. Results of DBS for dystonia appear
tobe moreconsistentlysuperiorinpatientswithprimary versussecondary formsofthe disorder. Patientswithsecondary dystonia,
due to a variety of causes, may still be candidates for DBS surgery, although the results may not be as consistently good. The
procedure is relatively safe with a small likelihood of morbidity and mortality. A randomized trial is needed to determine who are
the best patients and when it is best to proceed with surgery.
1.Introduction
Dystonia is a painful and severely disabling disease, whose
cause is unknown, but is believed to be disorder of the basal
ganglia. For patients with the rare, generalized form, treat-
ment options are limited, but include baclofen pumps, pe-
ripheral denervation surgery, and stereotactic surgery. While
lesioning the thalamus was originally the preferred surgical
treatment option for dystonia [1, 2], recent interest has
shifted the focus onto the globus pallidus internus (GPi).
This derived mainly from the noteworthy improvement
in dystonic symptoms associated with Parkinson’s disease
which have been demonstrated after pallidotomy [3–5].
Although there are multiple case reports of dystonia being
successfully treated with pallidotomy [6–10], there can be
signiﬁcant side eﬀects, and the beneﬁts may not be durable
[2]. With the development of DBS over the last decade, the
surgery has become safer, and the side eﬀects have become
easier to control. Moreover, as the disease progresses, stimu-
lation can be varied to improve outcomes.
Variable muscle groups may be involved to a diﬀering
extent and severity. The focal dystonias (e.g., Torticollis,
Writer’s cramp) involve a single body region while the gener-
alized dystonias involve wide spread axial and limb muscles.
The dystonias may be classiﬁed by three criteria: etiology,
age of onset (early versus late), and anatomical distribution
(focal, segmental, multifocal, and generalized). With regard
to etiology the classiﬁcation includes primary (idiopathic)
and secondary (symptomatic). Accurate estimates about
the prevalence of dystonia in the general population are
often confounded by confusion regarding the diagnosis [11].
Nutt et al.estimatedtheprevalencetobe29.5per100,000for
focal dystonias and 3.4 for 100,000 per generalized dystonias
[12]. A more recent collaborative epidemiologically study in
Europe estimated an annual prevalence of 15.2 per 100,000
withthemajoritycasesconsistingoffocaldystonias[13].The
age of onset of primary dystonia is bimodal in distribution
with peak incidences occurring at 9 (early onset) and 45 (late
onset) years of age [11].
The exact pathophysiology of the dystonias remains un-
kown. Neurophysiological studies suggest that a dysfunction
within the basal ganglia leads to loss of cortical inhibition,
resulting in excessive cortical activity, thus producing the
abnormal movements [14]. Only a minority of patients
with symptomatic generalized dystonia—namely, those with
Wilson’s disease, psychogenic dystonia, and dopa responsive
dystonia (DRD)—have speciﬁc treatment options [15]. As
a result, the evaluation of all adolescents and children with
new onset dystonia should include a levodopa trial and
should rule outWilson’s disease. The characteristic feature of
DRD is a signiﬁcant, sustained response of the Parkinsonian
and dystonic symptoms to low-dose levodopa. Therefore,2 ISRN Surgery
all pediatric cases of dystonia without a known etiology
should be treated with levodopa in the early stages. For the
remaining patients with dystonia the goal of treatment is to
improvesymptoms ratherthanaddresstheunderlyingcause.
Nonsurgical treatment aimed at controlling symptoms
include medications and botulinum toxin. Although mul-
tiple medications have been found to produce beneﬁt in
selected patients with dystonia, no single agent can consis-
tently relieve symptoms [16]. Botulinum toxin is currently
the primary treatment for many focal dystonias including
torticollis, blepharospasm, and spasmodic dysphonia [17,
18].
Surgery aimed at improving dystonic symptoms includes
targeted procedures of both peripheral and CNS structures.
Denervation procedures have been used, with some positive
results, primarily in the treatment of cervical dystonia
[19]. Progress in understanding the physiology of the basal
ganglia, reﬁned surgical techniques, and the discovery that
pallidotomy can improve “oﬀ state” dystonia in Parkinson’s
disease patients have led to renewed interest in CNS proce-
duresfor the treatment of dystonia [5, 20]. Published reports
have described improvement in symptoms of patients with
primary generalized dystonia undergoing pallidotomy [8,
21].Theprimary limitationofthisapproachisthatunilateral
pallidotomy may be insuﬃcient to treat axial disease while
bilateral pallidotomy is associated with signiﬁcant risk of
dysphagia, dysarthria, and cognitive dysfunction [22, 23].
Moreover, becausethese proceduresare irreversible,itis pos-
sible that they may interfere with future treatment options
which may become available with increased understanding
of the neurophysiological and genetic basis of dystonia.
2.DeepBrainStimulation
DeepBrain Stimulation(DBS)has the potential to overcome
these hurtles. It has signiﬁcant advantages over ablative pro-
cedures including the following.
Reversibility—if side eﬀects are noted, stimulation pa-
rameters can be adjusted through programming or the stim-
ulator turned oﬀ. This will allow patients to remain candi-
datesforfuturetherapiesthatmayariseasaresultofprogress
in molecular genetic research.
Programmability—unlike with ablative procedures, sti-
mulation parameters can be adjusted as needed over time to
improve the response and minimize the side eﬀects. More-
over,theprogrammabilityprovidesamechanismbywhich to
increase our understanding of the physiological of dystonia
and other movement disorders.
B i l a t e r a lt a r g e t i n g — t h ea b i l i t yt ot u r nt os t i m u l a t o r so ﬀ
combinedwith theminimal amount of tissue damagecaused
by the electrodes allows bilateral procedures to be performed
more safely as compared to ablative procedures.
The disadvantages of DBS include high costs, higher risk
of infection, the need for periodic battery replacement, and
the potential for hardware malfunction.
While there is currently no consensus as to the ideal
site for DBS implantation for the treatment of dystonia,
the thalamus, subthalamic nucleus, and globus pallidus have
been targeted successfully [24, 26, 27]. The methodology
for implanting electrodes is also variable. Target localization
at some centers still includes ventriculography [26, 27],
although CT and MRI are rapidly becoming more prevalent.
Implantation can occur while the patient is under general
anesthesia, although at most centers it is performed under
local anesthetic alone. While some centers perform bilateral
procedures staged over weeks or even months, others prefer
to implant simultaneous bilateral electrodes.
Coubes et al. have implanted both electrodes in a single
session under general anesthesia. The targeting was per-
formed based on MRI alone without intraoperative micro-
electrode recording (MER) [28]. By contrast Krauss and
colleagues performed the procedure under local anesthesia,
targeting the posteroventral lateral GPi using MER [29].
They subsequently perform macrostimulation with the DBS
electrode in order to determine thresholds and responses
prior to ﬁnalizing the electrode position.
Tagliati et al. treat medically refractory primary dystonia
with bilateral DBS electrodes implanted during a single ster-
eotactic procedure [16]. In most cases, the patients are im-
planted awake in order to facilitate MER. In the patients
who are either too young or too severely aﬀected by their
dystonic symptoms to tolerate awake surgery, they use ei-
ther dexmedetomidine hydrochloride or propofol for light
sedation.
At Wake Forest University, we generally implant both
electrodes in a single session to spare the dystonia patients
a second frame application. We have also found that the
younger patient population seen in dystonia is less likely to
undergo the brain shift often seen in the older population
when simultaneous burr holes are placed (unpublished
data). After completing MER targeting, macrostimulation
with the DBS electrode is performed to ensure that the
patient does not suﬀer from serious side eﬀects. Production
of abnormal visual scotomata is an evidence that the elec-
trode is too deep and may need to be withdrawn. Production
of motor contractions results from an electrode that is too
lateral, requiring that the electrode be moved medially. After
the target is anatomically and electrophysiologically reﬁned,
the electrode is secured to the calvarium using the Navigus
system. The proximal end is then tunneled in a subgaleal
fashion to the parietal region. After completing one side, the
same procedure is performed on the contralateral brain. The
proximal end of both electrodes can be tunneled to the same
parietal location. The extension sets and pulse generator(s)
are then implanted under general anesthesia during a second
procedure,typically3weeksaftertheelectrodeimplantation.
To determine whether a patient is a suitable candidate
for DBS implantation, the neurologist and neurosurgeon
must consider not only the motor status, but also the
cognitive, physiological, and overall medical condition. The
most suitable candidates appear to be those with segmen-
tal, generalized dystonia who have failed to respond to
botulinum toxin injections or medication and thus suﬀer
from continued pain and disability [30]. This screening
must include a levodopa trial in order to exclude patients
with DRD and should determine whether the symptom to
be treated with DBS is the primary source of disability.ISRN Surgery 3
Recent experience with DBS suggests that primary dystonia
(especially the DYT1-positive) responds more favorablythan
secondarydystonia [16,25,31].TheeﬀectsofDBSontardive
dystonia and myoclonic dystonia, while encouraging, have
been studied less extensively. The ideal timing of surgery is
debated, but it should be performed prior to the onset of
contractures of other orthopedic complications, in order to
maximize neurological rehabilitation.
3.ClinicalResults
Mundingerwastheﬁrst torecordtheuse ofDBSfordystonia
in 1977 [16]. He implanted 7 patients with cervical dystonia
with unilateral electrodes. They subsequentlyunderwent low
frequency, intermittent stimulation of the thalamic and sub
thalamic nuclei. They observed good results although the
follow-up period was short. Subsequentto this, DBSfor dys-
tonia was largely abandoned until the late 1980s. In light of
the favorable results achieved with pallidotomy for dystonia
at that time, DBS of the GPi soon re-emerged. Early results
of GPi DBS for dystonia were so encouraging that the FDA
granted a humanitarian device exemption (HDE) for the
Medtronic Activa DBS system for the treatment of primary
generalized dystonia in April 2003.
Patients with primary dystonia appear to respond better
than those with secondary dystonia. Patients with DYT1-
positive primary dystonia appear to derive the most beneﬁt,
with improvements of up to 90% on the Burke-Fahn-
Marsden Dystonia Rating Scale (BFMDRS) [25, 27, 31–34].
The DYT1 form is an inherited, generalized dystonia caused
by a single GAG deletion in the DYT1 gene located on chro-
mosome 9q. This gene encodes torsin A which is a member
of the family of AAA adenosine triphosphates. Although the
inheritance pattern of DYT1 gene mutation is autosomal
dominant, the phenotypic penetrance is 30% to 40%. The
DYT1 mutation is more common in the Ashkenazi Jewish
populations, but has also been identiﬁed in non-Jewish
Asian,European,andNorthAmericanfamilies. Patientswith
DYT1-positive dystonia most commonly present in child-
hood with limb dystonia, which may subsequently become
generalized.
Improvements in the tonic components tend to be more
gradual, and the maximal beneﬁt from DBS may not be
seen for 6–12 months. The results in patients with non-
DYT1 primary dystonia, while less impressive, are still quite
good [35, 36]. Positive results have also been reported in
casesoffamilial myoclonicdystonia, an autosomaldominant
disorder with onset in childhood or early adolescence.
Reports documenting the eﬀect of pallidal DBS on
secondary dystonia have been more varied and perhaps
less encouraging [25, 36, 37]. This subgroup of patients
has a more heterogeneous proﬁle with regard to etiology,
clinical manifestations, and prognosis. Chang et al. reported
long-term eﬀects of bilateral pallidal DBS for patients with
tardive dystonia secondary to neuroleptic medication use
[38]. The mean baseline BFMDRS score was 49.7 (range 20–
88). The followup lasted from 2 to 8 years during which
they observed a 62% improvement in the BFMDRS. 71% of
patients demonstrated sustained improvement at the time of
the last follow-up.
Speelmanetal.recentlyreviewedtheliteratureandfound
reports on 109 patients undergoing DBS for secondary dys-
tonia [39]. In most cases, the cause was tardive dystonia (38
patients), cerebral palsy (18 patients), myoclonus-dys-tonias
(12patients),orneurodegenerationwithbrain ironaccumu-
lation (13 patients). The remaining patients were distributed
under a wide variety of diagnoses ranging from rapid onset
dystonia parkinsonism to postanoxic secondary generalized
dystonia. The outcomes also varied widely based on the
diagnosis. Of those with tardive dystonia, 27 patients (69%)
experienced whether a good or very good outcome. In
those patients with myoclonus-dystonia, 12 (100%) received
a very good result. In patients with NBIA, 8/13 (64%)
obtained either good or very good outcome after pallidal
DBS electrode implantation.
Many of the patients with secondary dystonia have other
neurological disorders, including spasticity, seizures, demen-
tia, and cerebrovascular disease, or cerebellar symptoms that
may limit optimal response to surgery. Many studies report
littletonobeneﬁtorevenworsenedoutcomesaftertheirDBS
in secondary dystonia. The exception to this however may
be in patients with tardive dystonia which appear to respond
favorably to DBS. A normal brain MRI may be a predictor of
favorable response to surgery.
Coubes et al. have published the largest series to date of
GPiDBSfordystonia[28].Theyreportedontheirexperience
with 53 patients, including 15 with DYT1-positive primary
dystonia, 17 with non-DYT1 primary dystonia, and 21 with
secondary dystonia. Followup ranged from 6 months to 5
years. One year after surgery, the DYT1-positive patients
improved an average of 71% on their clinical scores. The
non-DYT1 patients improved 74% on average. Those with
secondary dystonia demonstrated an average improvement
of only 31%. The eﬃcacy of stimulation did not appear to
decrease with time. Complications included 1 lead fracture
and 3 patients with an infection.
Tagliati and colleagues implanted bilateral DBS leads
in the GPi of 12 patients with medically refractor primary
dystonia and 3 patients with secondary dystonia [16]. Seven
of the patients with primary dystonia were DYT1-positive.
Two of the DYT1-positive patients had undergone multiple
thalamotomy 30 years prior to DBS implantation. The 3
patients with secondary dystonia had a childhood history of
encephalitis or encephalopathy. Intraoperative MER, MRI,
and ﬂuoroscopy were all used to reﬁne the targeting of
the GPi. All patients were evaluated with the BFMDRS
before and after surgery. The DBS output settings were
titrated upward after surgery to achieve the best clinical
outcome. Optimal results were found at a high frequency
(130Hz) and with a large pulse width (210–400 microsec-
onds). Percent changes of BFMDRS scores were calculated
postoperatively at a minimum of 6 months of followup.
All of the patients with primary dystonia demonstrated
improvement in their BFMDRS scores (range 32–97%). The
improvement was found to be progressive over time with
an average improvement of 33.2% at 1 month, 47.2% at 3
months, 60.4% at 6 months, 72.9% at 1 year, and 78.9% at4 ISRN Surgery
2 years. Two of the DYT1-positive patients demonstrated an
improvement in the BFMDRS of 77% and 95%, respectively
at 3 years. The 3 patients with secondary dystonia showed
an average improvement of 32.6% on their BFMDRS scores.
The two DYT1-positive patients with prior thalamotomy
demonstrated results comparable to those observed in the
patients with secondary dystonia. Complications included 1
superﬁcial infection requiring lead revision and 2 fractured
wires.
Kumar et al. [40] and Coubes et al. [32]r e p o r t e d
one case each of an early onset, generalized dystonia that
improved signiﬁcantly after DBS of the GPi. Coubes et
al. subsequently reported on seven patients (6 children, 1
adult) with rapidly progressing,D Y T 1 - p o s i t i v eg e n e r a l i z e d
dystonia who underwent bilateral posteroventral GPi DBS
implantation [32]. The mean age at surgery was 14 years 6
months (range 8–27 years). Neurological status was assessed
pre- and postoperatively at selected intervals using the
BMFDRS. The duration of followup was at least 1 year for
all patients. Stimulation variables included high frequency
(130Hz), monopolar low voltage (1.6V), with continuous
stimulation on one or two contacts. Generalized dystonia
improved gradually over 3 months. There was a progressive
improvement in function with dystonic movements dis-
appearing over time. All six children managed learned to
walk without assistance. In the lone adult patient, secondary
spinal and lower limb deformities limited complete recovery
even though dystonia was signiﬁcantly improved. Pain
rapidly improved in all patients. Infection in one patient
required removal of the entire DBS system with successful
reimplantation 6 months later. No other adverse events
were reported. They documented an improvement ranging
from 60% to 100% in the BFMDS score at the one year
followup.
Yianni et al. reported their outcomes with two patients
suﬀering from DYT1-positive generalized dystonia who
underwent bilateral GPi DBS [36]. At followup times of six
and twelve months, respectively, they reported improvement
in the total BFMDS score of approximately 40% and
85%. This study also included 12 patients with DYT1-
negative dystonia, with seven patients having a young age
at disease onset. While the outcomes were highly varied,
they found an average improvement of 46% in the total
BFMDS score. Krauss et al. reported their experience with
two patients with a DYT1-negative generalized dystonia who
underwent bilateral GPi DBS. After two years of followup,
they discovered an improvement in the BFMDS motor score
of 70% to 80%.
More recently, Haridas et al. reported their result on
22 consecutive patients <21 years of age with primary
generalizeddystonia who underwentDBSimplantation[41].
The followup was quite good with all 22 patients reaching
1-year followup, 14 reaching 2 years, and 11 reaching 33
years. The motor subscores of the BFMDRS improved by
84%, 93%, and 94% at these follow-up points. Comparable
improvementswereseeninoverallfunctionandneedfororal
or intrathecal medications. No hemorrhages or neurological
complications of surgery were observed; however, the infec-
tion rate was signiﬁcant at 14%.
Vercueil et al. published their results with two patients
suﬀering from PKAN who underwent bilateral DBS implan-
tation in the ventral intermediate thalamic nuclei. With
a follow-up time of 120 months, one of the patients
demonstrated improvement of 26% in the BFMDS score. In
the same year, Trottenbergetal. reported on onepatientwith
tardive dystonia whose BFMDS score improved by 72% six
months after beginning pallidal DBS.
Andews et al. performed a metaregression analysis of
individual patient outcomes by reviewing results of pallidal
DBS in 466 patients from 157 papers published through
2010. The subclassiﬁcation of patients included 344 with
primary dystonia, 10 with myoclonus dystonia, 19 with neu-
rodegenerative dystonias, and 93 with secondary dysto-
nia. They concluded that patients with primary dystonia,
myoclonus dystonia, certain subtypes of heredodegenerative
dystonia, andtardivedystonia havea>50%averageimprove-
ment in dystonia rating following DBS. In patients with
primary generalized dystonia, a multiple regression analysis
revealed that lower baseline severity score, shorter duration
of symptoms, and DYT1 positive status were all associated
with a signiﬁcantly higher likelihood of improvement.
Patients with secondary dystonia and heredodegenerative
disorders had a more varied response, making conclusions
regarding predicted outcomes more diﬃcult.
4.Conclusion
Dystonia is a syndrome of sustained muscle contractions
producingabnormal postures, twisting, and repetitive move-
ments.Avarietyofforms havebeendescribed,most ofwhich
are refractory to medical therapy alone. DBS has been used
to treat several of these conditions but the success varies
according to the type of dystonia. The treatment of dystonia
with DBS is becoming increasingly common as evidenced by
the rising number of published case reports on the rise. The
most successful results appear to be in DYT1+ children or
young adults. The question arises as to whether or not other
genetic dystonias respond to GPi DBS. While patients with
primary dystonia appear to have superior results compared
to those with secondary forms of the disease, the latter
patients, in some cases, may still be candidates for DBS.
What is now needed is a randomized trial with long-term
followup to identify who are the best candidates, when best
to intervene with DBS, and where best to place the lead.
References
[1] I. S. Cooper, T. Cullinan, and M. Riklan, “The natural history
ofdystonia,”Advances in neurology,vol.14,pp.157–169,1976.
[2] C. Gros, P. Frerebeau, E. Perez-Dominguez et al., “Long
term results of stereotaxic surgery for infantile dystonia and
dyskinesia,” Neurochirurgia, vol. 19, no. 4, pp. 171–178, 1976.
[ 3 ] J .J a n k o v i c ,E .L a i ,L .B e n - A r i e ,J .K .K r a u s s ,a n dR .G r o s s m a n ,
“Levodopa-induced dyskinesias treated by pallidotomy,” Jour-
naloftheNeurological Sciences,vol.167,no.1,pp.62–67,1999.
[4] J. Jankovic, E. C. Lai, J. Krauss, and R. Grossman, “Surgical
treatment of levodopa-induced dyskinesias,” Advances in
Neurology, vol. 80, pp. 603–609, 1999.ISRN Surgery 5
[ 5 ]A .M .L o z a n o ,A .E .L a n g ,N .G a l v e z - J i m e n e ze ta l . ,“ E ﬀect of
GPi pallidotomy on motor function in Parkinson’s disease,”
The Lancet, vol. 346, no. 8987, pp. 1383–1387, 1995.
[ 6 ]R .P .I a c o n o ,S .M .K u n i y o s h i ,R .R .L o n s e r ,G .M a e d a ,A .M .
Inae, and S. Ashwal, “Simultaneous bilateral pallidoansotomy
for idiopathic dystonia musculorum deformans,” Pediatric
Neurology, vol. 14, no. 2, pp. 145–148, 1996.
[ 7 ]R .P .I a c o n o ,S .M .K u n i y o s h i ,a n dT .S c h o o n e n b e r g ,“ E x p e r i -
ence with stereotactics for dystonia: case examples,” Advances
in Neurology, vol. 78, pp. 221–226, 1998.
[8] W. G. Ondo, M. Desaloms, J. Jankovic, and R. G. Grossman,
“Pallidotomy for generalized dystonia,” Movement Disorders,
vol. 13, no. 4, pp. 693–698, 1998.
[ 9 ]J .L .V i t e k ,“ S u r g e r yf o rd y s t o n i a , ”Neurosurgery Clinics of
North America, vol. 9, no. 2, pp. 345–366, 1998.
[10] J. L. Vitek and R. A. E. Bakay, “The role of pallidotomy
in Parkinson’s disease and dystonia,” Current Opinion in
Neurology, vol. 10, no. 4, pp. 332–339, 1997.
[11] S. B. Bressman, D. De Leon, M. F. Brin et al., “Idiopathic
dystonia among Ashkenazi Jews: evidence for autosomal
dominantinheritance,” Annals of Neurology,v o l .2 6 ,n o .5 ,p p .
612–620, 1989.
[12] J. G. Nutt, M. D. Muenter, L. J. Melton III, A. Aronson,
and L. T. Kurland, “Epidemiology of dystonia in Rochester,
Minnesota,”AdvancesinNeurology,vol.50,pp.361–365,1988.
[13] T. T. Warner, “Sex-related inﬂuences on the frequency and age
of onset of primary dystonia,” Neurology,v o l .5 3 ,n o .8 ,p p .
1871–1873, 1999.
[14] A. Berardelli, J. C. Rothwell, M. Hallett, P. D. Thompson,
M. Manfredi, and C. D. Marsden, “The pathophysiology of
primary dystonia,”Brain, vol.121,no. 7,pp. 1195–1212,1998.
[15] R. L. Alterman and M. Tagliati, “Deep brain stimulation for
torsion dystonia in children,” Child’s Nervous System, vol. 23,
no. 9, pp. 1033–1040, 2007.
[ 1 6 ]M .T a g l i a t i ,J .S h i l s ,C .S u n ,a n dR .A l t e r m a n ,“ D e e pb r a i n
stimulation for dystonia,” Expert Review of Medical Devices,
vol. 1, no. 1, pp. 33–41, 2004.
[ 1 7 ]J .J a n k o v i ca n dM .F .B r i n ,“ T h e r a p e u t i cu s e so fb o t u l i n u m
toxin,” The New England Journal of Medicine, vol. 324, no. 17,
pp. 1186–1194, 1991.
[18] M. F. Lew, A. Brashear, and S. Factor, “The safety and eﬃcacy
of botulinum toxin type B in the treatment of patients with
cervical dystonia: summary of three controlled clinical trials,”
Neurology, vol. 55, no. 12, pp. S29–S35, 2000.
[19] C. M. Bertrand, “Selective peripheral denervation for spas-
modic torticollis: surgical technique, results, and observations
in 260 cases,” Surgical Neurology, vol. 40, no. 2, pp. 96–103,
1993.
[20] L. V. Laitinen, A. T. Bergenheim, and M. I. Hariz, “Leksell’s
posteroventral pallidotomy in the treatment of Parkinson’s
disease,” Journal of Neurosurgery, vol. 76, no. 1, pp. 53–61,
1992.
[21] A. M. Lozano, R. Kumar, R. E. Gross et al., “Globus pallidus
internus pallidotomy for generalized dystonia,” Movement
Disorders, vol. 12, no. 6, pp. 865–870, 1997.
[22] Z. Hua, G. Guodong, L. Qinchuan et al., “Analysis of
complications of radiofrequency pallidotomy,” Neurosurgery,
vol. 52, no. 1, pp. 89–101, 2003.
[23] J. L. Vitek, V. Chockkan, J. Y. Zhang et al., “Neuronal activity
in the basal ganglia in patients with generalized dystonia and
hemiballismus,”Annals of Neurology, vol. 46, no. 1, pp. 22–35,
1999.
[24] A. Kupsch, R. Benecke, J. M¨ uller et al., “Pallidal deep-brain
stimulation in primary generalized or segmental dystonia,”
The New England Journal of Medicine, vol. 355, no. 19, pp.
1978–1990, 2006.
[ 2 5 ] A .K u p s c h ,A .K u e h n ,S .K l a ﬀke et al., “Deep brain stimulation
in dystonia,” Journal of Neurology, vol. 250, supplement 1, pp.
I47–I52, 2003.
[26] T. Trottenberg, G. Paul, W. Meissner, K. Maier-Hauﬀ,C .
Taschner, and A. Kupsch, “Pallidal and thalamic neurostim-
ulation in severe tardive dystonia,” Journal of Neurology
Neurosurgery and Psychiatry, vol.70, no. 4, pp. 557–559, 2001.
[27] L. Vercueil, P. Pollak, V. Fraix et al., “Deep brain stimulation
in the treatment of severe dystonia,” Journal of Neurology,v o l .
248, no. 8, pp. 695–700, 2001.
[28] P. Coubes, N. Vayssiere, H. El Fertit et al., “Deep brain
stimulation for dystonia: surgical technique,” Stereotactic and
Functional Neurosurgery, vol. 78, no. 3-4, pp. 183–191, 2002.
[29] J. K. Krauss, J. Yianni, T. J. Loher, and T. Z. Aziz, “Deep brain
stimulation for dystonia,” Journal of Clinical Neurophysiology,
vol. 21, no. 1, pp. 18–30, 2004.
[30] J. Volkmannand R. Benecke, “Deep brain stimulationfordys-
tonia: patient selection and evaluation,” Movement Disorders,
vol. 17, no. 3, pp. S112–S115, 2002.
[31] L. Cif, X. Vasques, V. Gonzalez et al., “Long-term follow-up
of DYT1 dystonia patients treated by deep brain stimulation:
an open-label study,” Movement Disorders,v o l .2 5 ,n o .3 ,p p .
289–299, 2010.
[32] P. Coubes, A. Roubertie, N. Vayssiere, S. Hemm, and B.
Echenne, “Treatment of DYT1-generalised dystonia by stim-
ulation of the internal globus pallidus,” The Lancet, vol. 355,
no. 9222, pp. 2220–2221, 2000.
[33] J. L. Ostrem and P. A. Starr, “Treatment of dystonia with deep
brain stimulation,” Neurotherapeutics, vol. 5, no. 2, pp. 320–
330, 2008.
[34] M. Vidailhet, L. Vercueil, J. L. Houeto et al., “Bilateral deep-
brainstimulationoftheglobuspallidusinprimarygeneralized
dystonia,” The New England Journal of Medicine, vol. 352, no.
5, pp. 459–467, 2005.
[35] J.K.Krauss,T. J.Loher,R. Weigel,H. H.Capelle, S.Weber, and
J. M. Burgunder, “Chronic stimulation of the globus pallidus
internus for treatment of non-DYT1 generalized dystonia and
choreoathetosis: 2-year follow up,” Journal of Neurosurgery,
vol. 98, no. 4, pp. 785–792, 2003.
[ 3 6 ]J .Y i a n n i ,P .G .B a i n ,R .P .G r e g o r ye ta l . ,“ P o s t - o p e r a t i v e
progress of dystonia patients following globus pallidus inter-
nus deep brain stimulation,” European Journal of Neurology,
vol. 10, no. 3, pp. 239–247, 2003.
[37] H. Bronte-Stewart, “Surgical therapy for dystonia,” Current
Neurology and Neuroscience Reports, vol. 3, no.4, pp. 296–305,
2003.
[38] E. F. Chang, L. E. Schrock, P. A. Starr, and J. L. Ostrem,
“Long-term beneﬁt sustained after bilateral pallidal deep
brain stimulationin patients with refractory tardive dystonia,”
Stereotactic and Functional Neurosurgery, vol. 88, no. 5, pp.
304–310, 2010.
[39] J. D. Speelman, M. F. Contarino, P. R. Schuurman, M. A. J.
T i j s s e n ,a n dR .M .A .D eB i e ,“ D e e pb r a i ns t i m u l a t i o nf o r
dystonia: patient selection and outcomes,” European Journal
of Neurology, vol. 17, supplement 1, pp. 102–106, 2010.
[ 4 0 ]R .K u m a r ,A .D a g h e r ,W .D .H u t c h i s o n ,A .E .L a n g ,a n dA .M .
Lozano, “Globus pallidus deep brain stimulation for general-
ized dystonia: clinical and pet investigation,” Neurology,v o l .
53, no. 4, pp. 871–874, 1999.
[41] A. Haridas, M. Tagliati, I. Osborn et al., “Pallidal deep brain
stimulation for primary dystonia in children,” Neurosurgery,
vol. 68, no. 3, pp. 738–743, 2011.